[{"orgOrder":0,"company":"Citius Oncology","sponsor":"TenX Keane Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Oncology \/ TenX Keane Acquisition","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ TenX Keane Acquisition"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"AmerisourceBergen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Citius Oncology \/ AmerisourceBergen","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ AmerisourceBergen"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"McKesson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Oncology \/ McKesson","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ McKesson"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Oncology \/ Citius Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ Citius Oncology"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"Verix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Denileukin Diftitox","moa":"IL2RA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Oncology \/ Verix","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ Verix"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ Undisclosed"}]